MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 5,000 shares of the firm’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $4.41, for a total value of $22,050.00. Following the transaction, the director now owns 120,583 shares in the company, valued at $531,771.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
John Joseph Johnston also recently made the following trade(s):
- On Friday, January 26th, John Joseph Johnston sold 5,000 shares of MaxCyte stock. The stock was sold at an average price of $5.12, for a total value of $25,600.00.
MaxCyte Price Performance
Shares of MXCT traded down $0.13 during trading hours on Thursday, reaching $4.19. 609,632 shares of the company’s stock traded hands, compared to its average volume of 678,650. The firm has a market capitalization of $436.18 million, a price-to-earnings ratio of -11.27 and a beta of 1.36. MaxCyte, Inc. has a twelve month low of $2.45 and a twelve month high of $5.55. The business’s fifty day simple moving average is $4.64 and its two-hundred day simple moving average is $4.20.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
MXCT has been the topic of several research analyst reports. Craig Hallum assumed coverage on MaxCyte in a research note on Wednesday, November 29th. They set a “buy” rating and a $7.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of MaxCyte in a research report on Wednesday, March 13th. BTIG Research dropped their target price on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, March 13th. Finally, Stephens reaffirmed an “overweight” rating and issued a $11.00 target price on shares of MaxCyte in a research report on Wednesday, March 13th.
Get Our Latest Analysis on MXCT
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
- Five stocks we like better than MaxCyte
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Do ETFs Pay Dividends? What You Need to Know
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- 10 Best Airline Stocks to Buy
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.